Updated:
Pharmagreen Biotech Inc.
Pharmagreen Biotech Inc. is a Canadian biotech firm using tissue-culture propagation for agriculture and hemp, with a focus on clonal plantlet production.
Pharmagreen Biotech Inc.
Pharmagreen Biotech Inc. was incorporated in Canada but a public founding year is not widely published. The company originated to address inefficiencies in plant propagation for commercial agriculture, particularly the hemp and cannabis markets. Wealth origin is not attributed to a specific family or individual; the firm is structured as a public entity. The company specializes in micropropagation using tissue-culture labs to mass-produce clonal plantlets for hemp, medical cannabis, and other high-value crops. It serves growers in North America with a focus on Canada and the United States. The firm positions its tissue-culture techniques as a superior alternative to seeds, offering genetic consistency, faster growth, and year-round availability. It does not operate as an investment manager or family office; its core business is agricultural biotechnology and contract propagation. Confirmed partners or clients have not been publicly documented in press. Team size and total deployment are not publicly disclosed. The company does not report additional offices beyond its Canadian facility. It has not publicized a recent operational event within the last 24 months that is verifiable through named sources. The structural differentiator is its proprietary tissue-culture platform for commercial-scale plant cloning in regulated agricultural markets, which differs from both traditional seed suppliers and typical biotech companies focused on genetics modification. The firm's model relies on physical lab production rather than fund-based capital deployment.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
—
Corporate office
Canada
Sector focus
Frequently asked questions
Who runs investment decisions at Pharmagreen Biotech?
Pharmagreen Biotech is a public company, and its investment decisions are made by its board of directors and executive management. The firm's leadership has not been extensively documented in public filings beyond corporate listings.
How does Pharmagreen source proprietary deal flow?
Pharmagreen does not operate as an investment manager, so it does not source deal flow in the traditional family-office sense. Its business is generating revenue through contracts for plant propagation services with growers.
Is Pharmagreen structured as a single family office or a biotechnology firm?
Pharmagreen Biotech Inc. is a publicly traded biotechnology firm, not a family office. It does not manage external capital and has no relation to family-office structures.
What investment stages does Pharmagreen typically target?
Pharmagreen does not target investment stages. It operates as a production company, focusing on early-stage commercial plant production for growers.
Which sectors does Pharmagreen explicitly focus on?
The firm focuses on agriculture, primarily hemp and medical cannabis propagation using tissue-culture technology. It may serve broader plant-based agricultural sectors.
How is Pharmagreen related to its parent or related vehicles?
Pharmagreen is not affiliated with any known family office or larger holding company. It appears as an independent public entity.
Where does the underlying wealth come from?
The firm does not have a disclosed wealth origin from a specific individual or family, as it is a publicly traded biotechnology company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: